Idiopathic Pulmonary Fibrosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Pipeline Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Idiopathic Pulmonary Fibrosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Pipeline Therapies, Mechanism of Action, Route of Administration, and Developments

September 17
17:36 2021
Idiopathic Pulmonary Fibrosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Pipeline Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Idiopathic Pulmonary Fibrosis – Pipeline Insight, 2021,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Idiopathic Pulmonary Fibrosis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscapes. 

The report comprises Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Idiopathic Pulmonary Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Idiopathic Pulmonary Fibrosis pipeline products.   

  

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as FibroGen, Kadmon Corporation, Promedior, Galapagos, MediciNova, etc., are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis.

  • Emerging therapies such as Pamrevlumab, KD025, PRM-151, GLPG1690, Tipelukast, are expected to have a significant impact on the  Idiopathic Pulmonary Fibrosis market in the coming years.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs, associated with significant morbidity and poor prognosis. It is the most common form of fibrosing idiopathic interstitial pneumonia, is an inexorably progressive disease with a 5-year survival of ~20%.

Idiopathic Pulmonary Fibrosis Pipeline Therapies along with Key Players:

  • Pamrevlumab by FibroGen, 

  • KD025 by Kadmon Corporation, 

  • PRM-151 by Promedior, 

  • GLPG1690 by Galapagos, 

  • Tipelukast by MediciNova,

  • And others.

Get an overview of pipeline landscape @ Idiopathic Pulmonary Fibrosis Clinical Trials Analysis

Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: FibroGen, Kadmon Corporation, Promedior, Galapagos, MediciNova, and others.

  • Pipeline Therapies: Pamrevlumab, KD025, PRM-151, GLPG1690, Tipelukast, and others.

Table of Contents

1

Idiopathic Pulmonary Fibrosis Report Introduction

2

Idiopathic Pulmonary Fibrosis Executive Summary

3

Idiopathic Pulmonary Fibrosis Overview

4

Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6

Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7

Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8

Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9

Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10

Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11

Idiopathic Pulmonary Fibrosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Idiopathic Pulmonary Fibrosis Key Companies

14

Idiopathic Pulmonary Fibrosis Key Products

15

Idiopathic Pulmonary Fibrosis Unmet Needs

16 

Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17

Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18

Idiopathic Pulmonary Fibrosis Analyst Views

19

Appendix

20

About DelveInsight

Related Reports:

Idiopathic Pulmonary Fibrosis Market

DelveInsight’s ‘Idiopathic Pulmonary Fibrosis (IPF) – Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPFs in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Idiopathic Pulmonary Fibrosis Epidemiology

DelveInsight’s Multiple Myeloma – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/